Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: GlobalData
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp Reiterates FY 2013 Guidance; Issues Q4 2013 Guidance; EPS Guidance Below Analysts' Estimates

Monday, 28 Oct 2013 09:00am EDT 

Edwards Lifesciences Corp reiterated its fiscal 2013 guidance with sales of $2.0 billion to $2.1 billion and earnings per diluted share (EPS), excluding special items, of $3.00 to $3.10. For the fourth quarter of 2013, it expects total sales of $520 million to $550 million, and diluted earnings per share (EPS), excluding special items, to be between $0.81 and $0.85. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $2.05 billion and EPS of $3.07 for fiscal 2013; revenue of $547 million and EPS of $0.86 for the fourth quarter of 2013.